Skip to main content

Article Title Abstract (Partial) Journal Year PMID SOM Author
A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma. A regimen of escalating doses of thalidomide, in combination with bortezomib and high-dose melphalan (mel/vel/thal), was evaluated as a conditioning regimen for autologous stem cell transplantation (ASCT) in multiple myeloma (MM) patients with a prior transplant who had relapsed or achieved less than a complete remission following a prior ASCT. Thalidomide was dose escalated starting from 600 mg to 1000 mg on days -5 to -1 in a 3 x 3 design, bortezomib was administered at 1.6 mg/m(2) intravenously on days -4 and -1 and melphalan 200 mg/m(2) was administered on day -2. No dose-limiting toxicity was seen in the phase I portion of the trial. An additional 20 patients were enrolled at the maximum tolerated dose of thalidomide of 1000 mg daily. The overall response rate was 69% with 38% complete remission. Median PFS and OS were 9.3 and 65.4 months, respectively, with a median follow-up of 17.8 months. The most common grade 3-4 adverse events (AEs) were neutropenic fever (58.6%), mucositis (6.9%), and diarrhea (6.9%). Serious AEs included somnolence (13.8%) and tumor lysis syndrome (3.4%). The addition of high-dose thalidomide to bortezomib and melphalan as conditioning for salvage ASCT was well tolerated and was an effective conditioning regimen. Bone marrow transplantation 2019 31101891

Biran, Noa;

Vesole, David H. (Internal Medicine)

The forgotten class of drugs for multiple myeloma: HDAC inhibitors NA The Lancet. Haematology 2018 30501864

Biran, Noa;

Siegel, David S.;

Vesole, David H. (Internal Medicine)

Login to LibApps